• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges

    5/6/25 8:03:00 AM ET
    $INMD
    Biotechnology: Electromedical & Electrotherapeutic Apparatus
    Health Care
    Get the next $INMD alert in real time by email

    IRVINE, Calif., May 6, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, reports that the US District Court for the Central District of California granted InMode's motion for default judgment against the DHGate sellers and awarded InMode a permanent injunction and damages for the defendants' sales and promotion of counterfeit goods.

    InMode Logo (PRNewsfoto/InMode)

    The Court's decision aims to protect safety and uphold InMode's trademark rights. The injunction includes freezing the assets and halting the listings of the sellers involved in the counterfeit trade. The ruling favors InMode on all claims (trademark infringement, false designation of origin, and California unfair competition), and (1) granted a permanent injunction enjoining the sellers from infringing upon the MORPHEUS® and INMODE® trademarks, and (2) awarded InMode damages per defendant.

    "InMode maintains a zero-tolerance policy towards fraudulent business practices including counterfeit goods and for any platforms or sellers who are using, selling, or distributing false products," says Moshe Mizrahy, CEO of InMode. "We are committed to public safety and will continue to protect consumers from potential harm caused by unauthorized Morpheus8 devices."

    InMode has established a Verified Provider Program for Morpheus8, allowing certified clinics to showcase their authenticity and confirm they use genuine Morpheus8 technology. This initiative helps patients identify safe, authorized providers committed to delivering trusted InMode results.

    Patients in the United States of America and Canada seeking top-quality care from an authorized InMode provider using a trademarked Morpheus8 device can visit the Find a Provider tool at www.inmodemd.com.

    About InMode 

    InMode is a leading global provider of innovative medical technologies. InMode develops, manufactures, and markets devices harnessing novel radiofrequency ("RF") technology. InMode strives to enable new emerging surgical procedures as well as improve existing treatments. InMode has leveraged its medically accepted minimally invasive RF technologies to offer a comprehensive line of products across several categories for plastic surgery, gynecology, dermatology, otolaryngology, and ophthalmology. For more information about InMode and its wide array of medical technologies, visit www.inmodemd.com.

    Press Contact:

    Behrman Cesa Communications

    [email protected]

    Investor Contact:

    MS-IR LLC

    Miri Segal – Scharia

    [email protected]

    Tel: 917-607-8654

    Logo - https://mma.prnewswire.com/media/1064477/5298285/InMode_Logo.jpg

    Cision View original content to download multimedia:https://www.prnewswire.com/news-releases/inmode-granted-injunction-against-counterfeit-sales-of-morpheus8-radio-frequency-microneedling-devices-and-needle-cartridges-302446235.html

    SOURCE InMode Ltd.

    Get the next $INMD alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $INMD

    DatePrice TargetRatingAnalyst
    4/29/2025Buy → Neutral
    BTIG Research
    4/28/2025$22.00 → $16.00Outperform → Neutral
    Robert W. Baird
    10/17/2024$25.00Buy
    BTIG Research
    7/23/2024$21.00 → $19.00Buy → Hold
    Jefferies
    11/3/2023$52.00 → $24.00Buy → Neutral
    UBS
    10/13/2023$55.00 → $22.00Buy → Hold
    Canaccord Genuity
    3/29/2023$40.00Buy
    UBS
    2/17/2023Buy → Hold
    Needham
    More analyst ratings

    $INMD
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • InMode downgraded by BTIG Research

      BTIG Research downgraded InMode from Buy to Neutral

      4/29/25 8:06:22 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode downgraded by Robert W. Baird with a new price target

      Robert W. Baird downgraded InMode from Outperform to Neutral and set a new price target of $16.00 from $22.00 previously

      4/28/25 1:56:11 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • BTIG Research initiated coverage on InMode with a new price target

      BTIG Research initiated coverage of InMode with a rating of Buy and set a new price target of $25.00

      10/17/24 7:41:34 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Financials

    Live finance-specific insights

    See more
    • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

      Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.  The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p

      5/9/25 8:22:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode Reports First Quarter 2025 Financial Results; Quarterly Revenue of $77.9 Million Represents 3% Year-Over-Year Decrease

      In April 2025, Completed Recent Share Repurchase Program of 6.95 Million Shares  YOKNEAM, Israel, April 28, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD) ("InMode"), a leading global provider of innovative medical technologies, today announced its consolidated financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights: Quarterly GAAP revenues of $77.9 million, compared to $80.3 million in the first quarter of 2024.Quarterly revenues from consumables and service of $20.2 million, a decrease of 10% compared to the first quarter of 2024.GAAP operating income of $15.6 million, *non-GAAP operating income of $18.1 million.Total cash position of $512.9 million as

      4/28/25 7:00:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode to Report First Quarter 2025 Financial Results and Hold Conference Call on April 28, 2025, Expects Q1 Revenue Between $77.2M-$77.5M, Reiterates FY 2025 Revenue Guidance Between $395M-$405M

      Conference call to be held on Monday, April 28, 2025, at 8:30 a.m. Eastern Time YOKNEAM, Israel, April 14, 2025 /PRNewswire/ -- InMode Ltd. (Nasdaq: INMD), a leading global provider of innovative medical technologies, announced today that it expects to release its financial results for the first quarter 2025 before the Nasdaq market opens on Monday, April 28, 2025. InMode is currently finalizing its financial results for the first quarter of 2025. While complete financial information and operating data are not yet available, set forth below are certain preliminary results of I

      4/14/25 7:00:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • DOMA Perpetual Sends Letter Urging Board of Directors of InMode Ltd. to Resume Share Repurchase Program

      Believes the Board Should Immediately Resume and Accelerate Buybacks Asserts Board Should Remove Moshe Mizrahy as CEO of the Company MIAMI, May 9, 2025 /PRNewswire/ -- DOMA Perpetual Capital Management LLC, a significant stockholder of InMode Ltd. (NYSE: INMD) ("InMode"), today sent a letter to the Board of Directors of InMode (the "Board") urging the Board to continue its stock repurchase program and to replace its CEO.  The letter can be downloaded here The full text of the letter follows: May 9th, 2025 To the Board Members of InMode: For over a year, we have communicated p

      5/9/25 8:22:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode to Present at Upcoming Investor Conferences and Events

      YOKNEAM, Israel, May 7, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, today announced the participation at the following investor conferences: BNP 3rd Annual Aesthetics Day Presenters: Moshe Mizrahy, Chief Executive Officer and Yair Malca, Chief Financial Officer Format: Virtual fireside chat moderated by Navann Ty, Lead Equity Analyst and one-on-one meetings When: Monday, May 19, fireside chat at 11:00 am ET A live webcast of the presentation can be accessed here. Barclays West Coast Bus Trip Presenters: Yair Malca, Chief Financial Officer Format: In-person investor bus tour at InMode's North American headquarters When: Thurs

      5/7/25 8:30:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • InMode Granted Injunction Against Counterfeit Sales of Morpheus8 Radio Frequency Microneedling Devices and Needle Cartridges

      IRVINE, Calif., May 6, 2025 /PRNewswire/ -- InMode Ltd. (NASDAQ:INMD), a leading global provider of innovative medical technologies, reports that the US District Court for the Central District of California granted InMode's motion for default judgment against the DHGate sellers and awarded InMode a permanent injunction and damages for the defendants' sales and promotion of counterfeit goods. The Court's decision aims to protect safety and uphold InMode's trademark rights. The injunction includes freezing the assets and halting the listings of the sellers involved in the counte

      5/6/25 8:03:00 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

      SC 13G/A - InMode Ltd. (0001742692) (Subject)

      2/13/24 4:31:18 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G/A filed by InMode Ltd. (Amendment)

      SC 13G/A - InMode Ltd. (0001742692) (Subject)

      2/13/24 4:25:40 PM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form SC 13G filed by InMode Ltd.

      SC 13G - InMode Ltd. (0001742692) (Subject)

      2/6/24 9:36:39 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care

    $INMD
    SEC Filings

    See more
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      4/28/25 7:00:06 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • SEC Form 6-K filed by InMode Ltd.

      6-K - InMode Ltd. (0001742692) (Filer)

      4/3/25 7:07:38 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care
    • Amendment: SEC Form 6-K/A filed by InMode Ltd.

      6-K/A - InMode Ltd. (0001742692) (Filer)

      2/6/25 7:00:21 AM ET
      $INMD
      Biotechnology: Electromedical & Electrotherapeutic Apparatus
      Health Care